Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 +0.64%
Revenue Growth %: +23.1%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +23.1%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $30.09 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $125-135 million, versus the consensus of $128 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Accenture downgraded by TD Cowen on AI concerns
- Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
